Condition
Palmoplantaris Pustulosis
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
50%
2 of 4 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
4Total
P 2 (3)
P 3 (1)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04057937Phase 2CompletedPrimary
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis
NCT01845987Phase 2CompletedPrimary
A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis
NCT00353119Phase 3CompletedPrimary
A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis
NCT00301002Phase 2Completed
Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis
Showing all 4 trials